Objective. In order to study the role of the p53 tumour suppressor gene in the proliferation of rheumatoid arthritis (RA) synovium, we analysed the mutation of p53 in the synovial fibroblast-like type B synoviocyte from RA patients.
Rheumatoid arthritis (RA) is characterized by chronic cartilage and kept their transformation-appearing cellular shape [3] . RA synovium is thus able to be considered inflammation and destruction of cartilage and bone of as a locally invading tumour. Therefore, as in the case systemic joints. Although the pathogenesis of RA is still of malignant tumours in other tissues, dysfunction of unknown, the invasion by proliferated synovial tissue is oncogenes and/or tumour suppressor genes might also considered to be an important factor in the development be involved in the pathogenesis of RA. In fact, overof RA [1] . Among the various cell types in the hyperplasexpression of oncogenes, such as myc, ras, fos and egr-1, tic synovial tissue, fibroblast-like type B synoviocytes is demonstrated in RA synovium [4] . In addition, dyshave drawn much attention as they exhibit transformed function of the tumour suppressor gene has also been properties that may explain the invasive characteristics suggested. The p53 tumour suppressor gene is overof RA synovium. The fibroblast-like type B cells can expressed in the intimal lining of RA synovium, as well grow in vitro in an anchorage-independent manner and as in the cultured fibroblast-like type B cells from RA without contact inhibition [2] . More importantly, their patients [5, 6 ] . As normal p53 is hardly detected due to tumour cell-like properties have been shown in in vivo the very short half-life of less than 30 min and mutation experimental systems. The fibroblast-like type B cells in p53 often prolongs its half-life, thereby permitting its co-implanted with normal human cartilage into severe detection [7] , the p53 molecule in the RA synovium is combined immunodeficient (SCID) mice invaded the likely to be mutated. Considering that the p53 tumour suppressor gene is mutated in more than half of human Submitted 5 May 1999; revised version accepted 21 September 1999. tumours [8] and plays a critical role in cell cycle arrest of RA synovium might be at least in part caused by the (NH 4 ) 2 SO 4 , 0.1% Triton X-100, and 0.1 mg/ml nuclease-free bovine serum albumin (BSA). The PCR reacdefects in the p53 gene.
Recently, the somatic mutations in the p53 tumour tion was performed using a Gene Amp 2400 cycler (PE Applied Biosystems, Foster City, CA, USA). The temsuppressor gene have been demonstrated in RA synovium [11, 12] . All the mutations are caused by point perature profile was an initial 1 min at 94°C, followed by 35 cycles of 30 s at 94°C, 45 s at 55°C, 60 s at 72°C, mutations, resulting in variable distribution, both in sites and patterns. In order to understand the role of and a final 5 min at 72°C. The amplified p53 cDNAs were then subcloned into plasmid pBluescript SK+ p53 mutation in the growth of RA synovium in more detail, we looked for somatic mutations in the p53 gene (Stratagene), and transferred into Escherichia coli, DH5a. The transformed cells were grown on a LB plate in fibroblast-like synoviocytes from nine Japanese patients with RA.
containing 0.1 mg/ml ampicillin. At least 10 subclones of each cDNA except for patient 3 were isolated using an automated plasmid isolation system PI-100 ( Kurabo,
Patients and methods
Osaka, Japan). The screening for p53 mutations was performed using Synovial tissues were collected at the time of joint replacement from nine patients with RA and one the streamlined mutation detection method in which PCR products are post-labelled with two different fluoosteoarthritis (OA) patient. All the RA patients had been diagnosed as definite RA by the 1987 American rescent dyes in one tube, and analysed by automated capillary electrophoresis (PLACE ) using single-strand College of Rheumatology (ACR) criteria [13] . The tissue was minced, dispersed with collagenase and trypconformation polymorphism (SSCP) conditions as described previously [14] . Briefly, subclones were amplisin, and cultured. After 1 day of culture, non-adherent cells were removed, and adherent cells were cultivated, fied by PCR, treated with the Klenow fragment of DNA polymerase I to exchange the 3∞ terminal residues for leading to the exclusive growth of fibroblast-like type B synoviocytes. At confluence, the cells were trypsinized, fluorescent nucleotides, R110-dUTP or R6G-dCTP (PE Applied Biosystems), added to formamide, and heat split at a 1:3 ratio, and recultured. Synoviocytes from passages 2-4 were used in the experiments. A breast denatured at 90°C for 3 min. Electrophoresis was performed using a Prism 310 CE system (PE Applied cancer cell line MCF7 was used as a negative control for the somatic mutations of the p53 gene.
Biosystems). The effective length of the capillary for detection was 36 cm. The separation matrix was Total RNA was extracted from the cultured synoviocytes using ISOGEN (Nippongene, Tokyo, Japan).
5% performance optimized polymer (PE Applied Biosystems) in 1 × TBE buffer (89 m Tris, 89 m Reverse transcription was performed in 15 ml of reaction mixture with 8 mg of total RNA and random hexadeoxyboric acid, 2 m EDTA, pH 8.0) containing 10% glycerol. The running conditions were 15.0 kV at 25°C. nucleotides at 37°C for 60 min using the First-Strand cDNA Synthesis Kit (Pharmacia Biotech, Piscataway, In this analysis, mutations were detected as a difference in the retention time of the fluorescent products between NJ, USA). Two overlapping p53 cDNAs containing the regions from codons 102-249 (exons 4-7) or from the reference (a subclone with a normal sequence) and the samples, because the strands of the samples have codons 245-393 (exons 7-11) were amplified from the first-strand cDNA by polymerase chain reaction (PCR). different conformation if there are sequence changes and therefore migrate differently during electrophoresis The total volume of the reaction mixture was 10 ml containing 0.5 m of each of the two 5∞ phosphorylated [15] . The D detection time was estimated as the shift in the retention time of the samples from the average of primers ( Table 1) , 0.2 m of each of the four nucleotides, 1 ml of the first-strand cDNA, 0.025 U/ml of the reference. The presence of mutations was suspected when the D detection time was three times larger than PfuTurbo DNA polymerase (Stratagene, La Jolla, CA, USA), 5% dimethylsulphoxide (DMSO), 20 m the standard deviation of the reference. We previously analysed 30 mutations in three independent sequence Tris-HCl (pH 8. codons 245-393) were analysed by SSCP in nine RA patients. Based on the criteria for D detection time IARC p53 somatic mutation database, may be caused by artefactual mutations. described previously, 21 subclones were chosen and were subsequently subjected to sequencing analysis. Eleven of the 21 subclones did not have any mutations, while Discussion the remaining 10 subclones were carrying 10 mutations. Five (patients 1, 2, 6, 7 and 8) of the nine RA patients
The p53 tumour suppressor gene encodes a nuclear phosphoprotein with cancer-inhibiting properties, and had mutations in their p53 subclones ( Table 2) . Five functional mutations (A161V, G245D, R267Q, A347fs, is mutated in more than half of human cancers [8] . The p53 protein is induced by many genotoxic stresses which G375X ) were identified in four patients and the former four mutations have been registered in the International is followed by cell cycle arrest and apoptosis of the injured cells [17] . Most p53 mutations in the mutational Agency for Research on Cancer (IARC ) p53 somatic mutation database [16 ] , suggesting their contribution to hot spots of human cancer function in a dominantnegative fashion [18] , which interfere with the function tumorigenesis. Of these mutations, the mutation of G245D has been registered most frequently in the dataof normal protein, culminating in the monoclonal expansion of the cells with p53 mutation and the development base; 62 independent reports out of a total of 9378 p53 mutations in human tumours registered so far (March of cancer. Disruption of p53 function by a retroviral vector also results in the increased proliferation and 1999). Patient 1 displayed six mutations in total, two of which were the G245D mutation. The G245D mutation invasiveness and impaired apoptosis of the fibroblastlike synoviocytes [19] . was also detected in patient 7. Patient 2 had a frameshift mutation (A347fs) and patient 8 was carrying a nonsense Here, we studied exons 4-11 for mutation, which include most of the hot spots of the p53 gene [20] . Five mutation (G375X ), both of which lead to truncation of the p53 protein.
p53 somatic mutations with alterations at the amino acid level were identified in four of nine (44.4%) RA However, most of the mutations were identified only once, except in the case of G245D. Silent mutations patients in Japan. These mutations (A161V, G245D, R267Q, A347fs, G375X ) are likely to cause functional were detected at a frequency comparable to functional mutations. Furthermore, no significant differences in alteration of p53 because the former four were also identified in malignancies in other tissues and the latter, frequency were found between most of our RA patients and the control cell line MCF7 because we detected a although not found in other tumours, causes truncation of the p53 protein. It is strongly suggested that these silent mutation in two of 29 subclones of MCF7, which should have occurred during cDNA synthesis or cultivamutations are not caused by artefactual events during cDNA synthesis or cell culture, considering the high tion. The synoviocytes from an OA patient were also studied for p53 mutation and only one of 34 subclones number of transition mutations and identity with mutations found in the p53 database. All the mutations but was positive for mutation (data not shown). The frequency was as low as that of the control cell line MCF7.
G245D were identified only once in the subclones, while G245D was identified in two subclones in patient 1 and It is suggested that some of the mutations in our study, especially those that have not been registered in the in one clone in patient 7. carrying the p53 mutation is difficult to estimate as none increase the sample size and to study G245D mutations in RA synovium. of the two previous reports (one from the USA and the other from Europe) as well as our study from Japan studied the entire coding region [11, 12] . However,
